252 related articles for article (PubMed ID: 28651817)
61. [Advances in mechanism of traditional Chinese medicine in inhibiting angiogenesis in ovarian cancer].
Tang MY; Ding DN; Xie YY; Shen F; Li J; Liu FY; Han FJ
Zhongguo Zhong Yao Za Zhi; 2023 Dec; 48(24):6572-6581. PubMed ID: 38212017
[TBL] [Abstract][Full Text] [Related]
62. Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.
Colombo N; Conte PF; Pignata S; Raspagliesi F; Scambia G
Crit Rev Oncol Hematol; 2016 Jan; 97():335-48. PubMed ID: 26555461
[TBL] [Abstract][Full Text] [Related]
63. Ovarian cancer stem cells: What progress have we made?
Al-Alem LF; Pandya UM; Baker AT; Bellio C; Zarrella BD; Clark J; DiGloria CM; Rueda BR
Int J Biochem Cell Biol; 2019 Feb; 107():92-103. PubMed ID: 30572025
[TBL] [Abstract][Full Text] [Related]
64. The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review.
Chellappan DK; Leng KH; Jia LJ; Aziz NABA; Hoong WC; Qian YC; Ling FY; Wei GS; Ying T; Chellian J; Gupta G; Dua K
Biomed Pharmacother; 2018 Jun; 102():1127-1144. PubMed ID: 29710531
[TBL] [Abstract][Full Text] [Related]
65. Angiogenesis of the ovary.
Abulafia O; Sherer DM
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):240-6. PubMed ID: 10649185
[TBL] [Abstract][Full Text] [Related]
66. Cancer stem cells targeting agents--a review.
Shi AM; Tao ZQ; Li H; Wang YQ; Zhao J
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(21):4064-7. PubMed ID: 26592827
[TBL] [Abstract][Full Text] [Related]
67. Anti-angiogenic therapy in ovarian cancer: current situation & prospects.
Liu Y; Luo Y; Cai M; Shen P; Li J; Chen H; Bao W; Zhu Y
Indian J Med Res; 2021 May; 154(5):680-690. PubMed ID: 35532586
[TBL] [Abstract][Full Text] [Related]
68. Glioma stem cells: markers, hallmarks and therapeutic targeting by metformin.
Najbauer J; Kraljik N; Németh P
Pathol Oncol Res; 2014 Oct; 20(4):789-97. PubMed ID: 25168767
[TBL] [Abstract][Full Text] [Related]
69. Metformin and cancer stem cells: old drug, new targets.
Bednar F; Simeone DM
Cancer Prev Res (Phila); 2012 Mar; 5(3):351-4. PubMed ID: 22389436
[TBL] [Abstract][Full Text] [Related]
70. An iron hand over cancer stem cells.
Hamaï A; Cañeque T; Müller S; Mai TT; Hienzsch A; Ginestier C; Charafe-Jauffret E; Codogno P; Mehrpour M; Rodriguez R
Autophagy; 2017 Aug; 13(8):1465-1466. PubMed ID: 28613094
[TBL] [Abstract][Full Text] [Related]
71. Angiogenesis in ovarian carcinoma: a formidable biomarker.
Kohn EC
Cancer; 1997 Dec; 80(12):2219-21. PubMed ID: 9404697
[No Abstract] [Full Text] [Related]
72. Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance.
Yue H; Lu X
Acta Biochim Biophys Sin (Shanghai); 2023 Apr; 55(6):938-947. PubMed ID: 37021977
[TBL] [Abstract][Full Text] [Related]
73. Ovarian cancer: Novel molecular aspects for clinical assessment.
Palmirotta R; Silvestris E; D'Oronzo S; Cardascia A; Silvestris F
Crit Rev Oncol Hematol; 2017 Sep; 117():12-29. PubMed ID: 28807232
[TBL] [Abstract][Full Text] [Related]
74. Modelling: Computing cancer.
Savage N
Nature; 2012 Nov; 491(7425):S62-3. PubMed ID: 23320290
[No Abstract] [Full Text] [Related]
75. Patterns of Cancer Stem Cell Negotiation with Breast Cancer Anti-angiogenic Therapy.
Darvishi B; Farahmand L; Majidzadeh-A K
Breast J; 2017 Sep; 23(5):612-614. PubMed ID: 28370769
[No Abstract] [Full Text] [Related]
76. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.
Vazquez-Martin A; López-Bonetc E; Cufí S; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
Drug Resist Updat; 2011; 14(4-5):212-23. PubMed ID: 21600837
[TBL] [Abstract][Full Text] [Related]
77. Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles?
Ferrara N
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059427
[No Abstract] [Full Text] [Related]
78. Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-like Cells using the Three-dimensional Co-culture System, NICO-1.
Miyagawa Y; Nagasaka K; Yamawaki K; Mori Y; Ishiguro T; Hashimoto K; Koike R; Fukui S; Sugihara T; Ichinose T; Hiraike H; Kido K; Okamoto K; Enomoto T; Ayabe T
J Vis Exp; 2020 Dec; (166):. PubMed ID: 33346189
[TBL] [Abstract][Full Text] [Related]
79. Ovarian cancer stem cells: elusive targets for chemotherapy.
Guddati AK
Med Oncol; 2012 Dec; 29(5):3400-8. PubMed ID: 22638913
[TBL] [Abstract][Full Text] [Related]
80. Ovarian cancer stem cells: a new target for cancer therapy.
Zhan Q; Wang C; Ngai S
Biomed Res Int; 2013; 2013():916819. PubMed ID: 23509802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
